Surmodics’s Return On Capital Employed Insights
Surmodics (NASDAQ:SRDX) brought in sales totaling $23.00 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 873.01%, resulting in a loss of $2.81 million.
Needham Maintains Buy on Surmodics, Lowers Price Target to $58
Needham analyst Mike Matson maintains Surmodics (NASDAQ:SRDX) with a Buy and lowers the price target from $70 to $58.
Surmodics Q1 EPS $(0.13) Beats $(0.31) Estimate, Sales $23.00M Miss $23.71M Estimate
Surmodics (NASDAQ:SRDX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.31) by 58.06 percent. This is a 750 percent decrease over earnings of $0.02 per share from the same
Earnings Scheduled For February 3, 2022
Companies Reporting Before The Bell
• Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter.
Needham Maintains Buy on Surmodics, Lowers Price Target to $70
Needham analyst Mike Matson maintains Surmodics (NASDAQ:SRDX) with a Buy and lowers the price target from $76 to $70.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Needham Maintains Buy on Surmodics, Raises Price Target to $76
Needham analyst Mike Matson maintains Surmodics (NASDAQ:SRDX) with a Buy and raises the price target from $68 to $76.
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)